{"id":"NCT03505099","sponsor":"Novartis Gene Therapies","briefTitle":"Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2","officialTitle":"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-02","primaryCompletion":"2021-06-15","completion":"2021-06-15","firstPosted":"2018-04-23","resultsPosted":"2022-01-11","lastUpdate":"2022-09-07"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Muscular Atrophy"],"interventions":[{"type":"BIOLOGICAL","name":"onasemnogene abeparvovec-xioi","otherNames":["Zolgensma"]}],"arms":[{"label":"onasemnogene abeparvovec-xioi","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2","primaryOutcome":{"measure":"Cohort 1: Number of Participants Who Achieved Sitting Alone for at Least 30 Seconds","timeFrame":"From Day 1 up to 18 months of age visit","effectByArm":[{"arm":"Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":16,"countries":["United States","Australia","Belgium","Canada","Japan","United Kingdom"]},"refs":{"pmids":["35715567","35715566","34383289"],"seeAlso":["https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17902"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":14},"commonTop":["Pyrexia","Upper respiratory tract infection","Diarrhoea","Teething","Aspartate aminotransferase increased"]}}